期刊
EUROPEAN JOURNAL OF HAEMATOLOGY
卷 89, 期 4, 页码 288-293出版社
WILEY
DOI: 10.1111/j.1600-0609.2012.01825.x
关键词
acute myeloid leukemia; STAT5; phosphorylation; prognosis
类别
资金
- Cleveland Clinic Leukemia Program
- Department of Pathology
Background Constitutive activation of STAT5 (by phosphorylation) has been identified in a number of malignancies, including acute myeloid leukemia (AML). Objectives We investigated whether the level of phosphorylated STAT5 (pSTAT5) expression correlates with clinical outcome in AML. Methods Adult patients with newly diagnosed AML receiving induction chemotherapy and with an available diagnostic bone marrow were evaluated. Results Forty-two percent of patients had pSTAT5 expression >0 on immunohistochemical analysis of fixed bone marrow core biopsies. In multivariable analyses, controlling for age, history of antecedent hematologic disorder, cytogenetic risk, and WBC at diagnosis, pSTAT5 expression was significantly associated with an increased risk of death (HR 1.96, 95% CI 1.193.23, P similar to=similar to 0.008) and of relapse after achieving complete remission (HR 2.31, 95% CI 1.164.63, P similar to=similar to 0.018). Conclusions Validation of pSTAT5's prognostic value requires additional study in a larger group of uniformly treated patients. However, our data suggests that targeting this signaling pathway in AML may improve the outcome of patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据